Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas.
Division of Pediatric Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Pediatr Pulmonol. 2020 Aug;55(8):2074-2081. doi: 10.1002/ppul.24822. Epub 2020 Jun 8.
Patients with pulmonary Langerhans cell histiocytosis (LCH) typically have a benign course but may have extensive cystic lung disease with rare life-threatening complications including multiple and recurrent pneumothoraces and respiratory failure. We report seven severely affected pediatric patients treated with chemotherapy, aggressive chest tube management, and pleurodesis of whom five survived. Patients with extraordinary amounts of pulmonary cystic disease and multiple pneumothoraces due to LCH can have remarkable, curative outcomes with early recognition, optimal LCH-directed therapy, and supportive care.
患有肺朗格汉斯细胞组织细胞增生症(LCH)的患者通常具有良性病程,但可能患有广泛的囊性肺疾病,罕见危及生命的并发症,包括多发性和复发性气胸和呼吸衰竭。我们报告了 7 例接受化疗、积极的胸腔引流管管理和胸膜固定术治疗的严重受影响的儿科患者,其中 5 例存活。由于 LCH 导致肺部囊性疾病和多发性气胸的患者,如果早期发现、采用最佳的 LCH 靶向治疗和支持性护理,可获得显著的、治愈性的结果。